SHIRE PLC: Director/PDMR Shareholding

Director/PDMR Share Dealings 
April 1, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
that it was notified on March 31, 2014 that on that day Ordinary Shares
("Shares") and American Depository Shares ("ADSs") of the Company, as set out
below, had been awarded under the Shire Executive Annual Incentive Plan
("EAIP") to Persons Discharging Managerial Responsibility ("PDMRs"). The Shares
and ADSs were acquired on March 31, 2014 at prices of £29.8997 per Share and
$147.64 per ADS. 


                                           Type of       Number of     
                                          Security                     
                                                         Securities    


                                                                   
Flemming Ornskov                            ADSs           2,703        
                                                                   
Tatjana May                                Shares          4,176        
The awards will normally be released to participants after a period of three
years. One ADS is equal to three Shares. 
In addition, the Company was notified on March 31, 2014 of the release of the
following Shares awarded in 2011 under the EAIP. 


                                         Number of    Number of Shares
                                          Shares      sold to satisfy 
                                          released    tax liabilities 


                                                                  
Tatjana May                                4,517                 2,139 
On March 31, 2014 sufficient Shares were sold to satisfy tax liabilities as set
out above. The Shares were sold at a price of £29.8076 per Share. 
The above transactions in Shares and ADSs took place on the London Stock
Exchange and NASDAQ respectively. 
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules. 
Tony Guthrie
Deputy Company Secretary 
For further information please contact: 
Investor Relations                                                              
                                                                           
Laurie Stelzer                          lstelzer@shire.com   +1 781 482 0733    
                                                                           
Eric Rojas                              erojas@shire.com     +1 781 482 0999    
                                                                           
Sarah Elton-Farr                        seltonfarr@shire.com +44 1256 894157    
Notes to editors 
Shire enables people with life-altering conditions to lead better lives. 
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs. 
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and
Internal Medicine and we are developing treatments for symptomatic conditions
treated by specialist physicians in other targeted therapeutic areas. 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 
Press Release                                      
                                              
www.shire.com                                      
END 
-0- Apr/01/2014 11:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.